People · Operator
Named in public records as an officer, director or promoter · active 2011–2012 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | — | Biotechnology | Series C | $108.8M | $3.1B | 2011 |
Eran D. Nadav at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Eran D. Nadav on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ben Auspitz | 1 | 9 |
| Eran Nadav | 1 | 4 |
| William Aliski | 1 | 4 |
| Marten Steen | 1 | 3 |
| EMIL KAKKIS | 1 | 2 |
| VIMAL D. SRIVASTAVA | 1 | 1 |
| THOMAS D. KASSBERG | 1 | 1 |
| STEVEN D. JUNGLES | 1 | 1 |
| CORDELIA D. LEONARD | 1 | 1 |
| Ben D. Auspitz | 1 | 1 |
| JOHN D. DITTON | 1 | 1 |
| William D. Aliski | 1 | 1 |
| Marten D. Steen | 1 | 1 |
| Emil D. Kakkis | 1 | 1 |
| SHALINI D. SHARP | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.